Trial SAKK 38/19 will investigate whether the addition of the active substance acalabrutinib to standard treatment can improve its efficacy against specific mutations. Treatment safety and tolerance will also be assessed.

Around 260 patients with a confirmed DLBCL diagnosis whose disease has not yet been treated with medications or other treatment methods can participate in the trial.

For more information on where and how this trial is conducted, consult the trial website.